Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
This is a case of one patient who was treated with a bortezomib-based desensitization regimen to treat sensitization obtained though a previous transplant lost to chronic rejection. This regimen successfully convert a positive crossmatch to negative, prevented both hyperacute and acute rejections out to 3-months post transplant, and was without any noticeable side effects. This account demonstrates that desensitization by bortezomib combined with plasmapheresis and low-dose IVIG is a possible way to transplant a highly sensitized patient.
Zhu
Lan
L
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lin
Zhengbin
Z
Xiang
Ying
Y
Liu
Shenwei
S
Chen
Gang
G
D000328:Adult; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood; D003888:Desensitization, Immunologic / Q000379:methods*; D006085:Graft Survival; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D007680:Kidney Neoplasms / Q000276:immunology*; D019520:Living Donors; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D016896:Treatment Outcome
D001897:Boronic Acids; D007518:Isoantibodies; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003404:Creatinine